Knockdown of Programmed Death 1 Inhibited Progression of Papillary Thyroid Carcinoma in Mice.

IF 1 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Protein and Peptide Letters Pub Date : 2023-01-01 DOI:10.2174/0929866530666230306112912

Hui Wang, Qianqian Chu, Shihong Ma, Ying Tao

{"title":"Knockdown of Programmed Death 1 Inhibited Progression of Papillary Thyroid Carcinoma in Mice.","authors":"Hui Wang, Qianqian Chu, Shihong Ma, Ying Tao","doi":"10.2174/0929866530666230306112912","DOIUrl":null,"url":null,"abstract":"Background: PD-L1 and PD1 mainly focused on melanoma, lung cancer and other tumors, while the related studies on early lymph node metastasis of papillary thyroid carcinoma were rarely reported.Objective: For elucidating the role of programmed death 1 (PD1)/programmed death ligand 1 (PD-L1) pathway in tumor growth of papillary thyroid carcinoma (PTC).Methods: Human thyroid cancer cell line and human normal thyroid cell line were obtained and transfected with si-PD1 or pCMV3-PD1 for the construction of PD1 knockdown or overexpression models. BALB/c mice were purchased for in vivo studies. Nivolumab was implemented for in vivo inhibition of PD1. Western blotting was performed for determining protein expression, while RTqPCR was used to measure relative mRNA levels.Results: The PD1 and PD-L1 levels were both significantly upregulated in PTC mice, while the knockdown of PD1 downregulated both PD1 and PD-L1 levels. Protein expression of VEGF and FGF2 was increased in PTC mice, while si-PD1 decreased their expression. Silencing of PD1 using si-PD1 and nivolumab both inhibited tumor growth in PTC mice.Conclusion: Suppressing PD1/PD-L1 pathway significantly contributed to the tumor regression of PTC in mice.","PeriodicalId":20736,"journal":{"name":"Protein and Peptide Letters","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Protein and Peptide Letters","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2174/0929866530666230306112912","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: PD-L1 and PD1 mainly focused on melanoma, lung cancer and other tumors, while the related studies on early lymph node metastasis of papillary thyroid carcinoma were rarely reported.

Objective: For elucidating the role of programmed death 1 (PD1)/programmed death ligand 1 (PD-L1) pathway in tumor growth of papillary thyroid carcinoma (PTC).

Methods: Human thyroid cancer cell line and human normal thyroid cell line were obtained and transfected with si-PD1 or pCMV3-PD1 for the construction of PD1 knockdown or overexpression models. BALB/c mice were purchased for in vivo studies. Nivolumab was implemented for in vivo inhibition of PD1. Western blotting was performed for determining protein expression, while RTqPCR was used to measure relative mRNA levels.

Results: The PD1 and PD-L1 levels were both significantly upregulated in PTC mice, while the knockdown of PD1 downregulated both PD1 and PD-L1 levels. Protein expression of VEGF and FGF2 was increased in PTC mice, while si-PD1 decreased their expression. Silencing of PD1 using si-PD1 and nivolumab both inhibited tumor growth in PTC mice.

Conclusion: Suppressing PD1/PD-L1 pathway significantly contributed to the tumor regression of PTC in mice.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

敲除程序性死亡1抑制小鼠甲状腺乳头状癌的进展。

背景:PD-L1和PD1主要集中于黑色素瘤、肺癌等肿瘤，而甲状腺乳头状癌早期淋巴结转移的相关研究很少报道。目的:探讨程序性死亡1 (PD1)/程序性死亡配体1 (PD-L1)通路在甲状腺乳头状癌(PTC)肿瘤生长中的作用。方法:获取人甲状腺癌细胞系和人正常甲状腺细胞系，转染si-PD1或pCMV3-PD1，构建PD1过表达或敲低模型。购买BALB/c小鼠进行体内研究。Nivolumab用于体内抑制PD1。Western blotting检测蛋白表达，RTqPCR检测相对mRNA水平。结果:PTC小鼠的PD1和PD-L1水平均显著上调，而PD1的下调使PD1和PD-L1水平均下调。PTC小鼠中VEGF和FGF2蛋白表达升高，si-PD1蛋白表达降低。使用si-PD1和纳武单抗沉默PD1均可抑制PTC小鼠的肿瘤生长。结论:抑制PD1/PD-L1通路可显著促进小鼠PTC肿瘤消退。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Protein and Peptide Letters 生物-生化与分子生物学

CiteScore

2.90

自引率

0.00%

发文量

审稿时长

2 months

期刊介绍： Protein & Peptide Letters publishes letters, original research papers, mini-reviews and guest edited issues in all important aspects of protein and peptide research, including structural studies, advances in recombinant expression, function, synthesis, enzymology, immunology, molecular modeling, and drug design. Manuscripts must have a significant element of novelty, timeliness and urgency that merit rapid publication. Reports of crystallization and preliminary structure determination of biologically important proteins are considered only if they include significant new approaches or deal with proteins of immediate importance, and preliminary structure determinations of biologically important proteins. Purely theoretical/review papers should provide new insight into the principles of protein/peptide structure and function. Manuscripts describing computational work should include some experimental data to provide confirmation of the results of calculations. Protein & Peptide Letters focuses on: Structure Studies Advances in Recombinant Expression Drug Design Chemical Synthesis Function Pharmacology Enzymology Conformational Analysis Immunology Biotechnology Protein Engineering Protein Folding Sequencing Molecular Recognition Purification and Analysis